Pancreatic Cancer Research

ResearcherUniversity of MiamiActive in the last 2 years

Moh'd M. Khushman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3095-5073; OpenAlex author ID A5087036882. Sources: OpenAlex.

Their work

Papers
13
Trials
0
Grants
0
Labs led
0
Collaborators
54
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 13

  1. Quantitative dynamic contrast-enhanced magnetic resonance imaging for early assessment of treatment response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00330-026-12810-2↗
  2. Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.neo.2023.100951↗
  3. Detection of mitochondrial DNA mutations in circulating mitochondria-originated extracellular vesicles for potential diagnostic applications in pancreatic aden… Co-author DOI 10.1038/s41598-022-22006-5↗
  4. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-3581↗
  5. Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer. Co-author DOI 10.1074/jbc.ra119.011748↗
  6. Comprehensive Analysis of Expression, Clinicopathological Association and Potential Prognostic Significance of RABs in Pancreatic Cancer. Co-author DOI 10.3390/ijms21155580↗
  7. Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth fact… Co-author DOI 10.4103/jcrt.jcrt_729_18↗
  8. Exosomal markers (CD63 and CD9) expression and their prognostic significance using immunohistochemistry in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/jgo.2018.07.02↗
  9. Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enz… Co-author DOI 10.1038/bjc.2017.18↗
  10. Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward. Co-author DOI 10.3390/ijms18040779↗
  11. Deep sequencing and in silico analyses identify MYB-regulated gene networks and signaling pathways in pancreatic cancer. Co-author DOI 10.1038/srep28446↗
  12. MYB Promotes Desmoplasia in Pancreatic Cancer through Direct Transcriptional Up-regulation and Cooperative Action of Sonic Hedgehog and Adrenomedullin. Co-author DOI 10.1074/jbc.m116.732651↗
  13. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2015.08.010↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Seema Singh · 8 shared papers, 2016–2022 · strength 0.75
  2. Ajay P. Singh · 8 shared papers, 2016–2022 · strength 0.75
  3. Mohammad Aslam Khan · 5 shared papers, 2017–2022 · strength 0.55
  4. Arun Bhardwaj · 5 shared papers, 2016–2019 · strength 0.34
  5. Girijesh Kumar Patel · 4 shared papers, 2017–2020 · strength 0.32
  6. Sanjeev K. Srivastava · 4 shared papers, 2016–2020 · strength 0.30
  7. Santanu Dasgupta · 2 shared papers, 2020–2022 · strength 0.30
  8. Shashi Anand · 2 shared papers, 2020–2022 · strength 0.30
  9. Harrison Kim · 1 shared paper, 2026 · strength 0.24
  10. Martin D. Holland · 1 shared paper, 2026 · strength 0.24
  11. John Bart Rose · 1 shared paper, 2026 · strength 0.24
  12. Desiree E. Morgan · 1 shared paper, 2026 · strength 0.24
  13. Midhun Malla · 1 shared paper, 2026 · strength 0.24
  14. Dana Backlund Cardin · 1 shared paper, 2026 · strength 0.24
  15. Mehmet Akce · 1 shared paper, 2026 · strength 0.24
  16. Sushanth Reddy · 1 shared paper, 2026 · strength 0.24
  17. Bassel F. El‐Rayes · 1 shared paper, 2026 · strength 0.24
  18. Upender Manne · 1 shared paper, 2024 · strength 0.20
  19. Farrukh Afaq · 1 shared paper, 2024 · strength 0.20
  20. Sooryanarayana Varambally · 1 shared paper, 2024 · strength 0.20
  21. Sumit Agarwal · 1 shared paper, 2024 · strength 0.20
  22. Priyabrata Mukherjee · 1 shared paper, 2024 · strength 0.20
  23. Subhash C. Chauhan · 1 shared paper, 2024 · strength 0.20
  24. Kunwar Somesh Vikramdeo · 1 shared paper, 2022 · strength 0.16
  25. Martin J. Heslin · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.